• 1
    Olivier P, Montastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf 2006; 15: 80812.
  • 2
    Clarke A, Deeks J, Shakir SAW. An assessment of the publically desseminated evdience of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006; 29: 17581.
  • 3
    Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 38596.
  • 4
    House of Commons Committee of Public Accounts. Safety, Quality, Efficacy: Regulating Medicines in the UK. London: The Stationery Office, 2003.
  • 5
    Safety, Quality, Efficacy: Regulating Medicines in the UK. London: National Audit Office, 2003.
  • 6
    Metters J. Report of an Independent Review of Access to the Yellow Card Scheme. London: The Stationery Office, 2004.
  • 7
    House of Commons Health Committee. The Influence of the Pharmaceutical Industry. London: The Stationery Office, 2005.
  • 8
    BMA Board of Science. Reporting adverse drug reactions: a guide for healthcare professionals. London: BMA, 2006.
  • 9
    Clark RC, Maxwell SR, Kerr S, Cuthbert M, Buchanan D, Steinke D, Webb DJ, Bateman ND. The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions. Drug Saf 2007; 30: 35766.
  • 10
    Inman W, Pearce GL. Prescriber profile and post-marketing surveillance. Lancet 1993; 342: 65861.
  • 11
    Florentinus SR, Heerdink ER, Groenewegen PP, De Bakker D, Van Dijk L, Fabiënne Greins AMG, Leufkins HGM. Who are the early prescribers of new drugs? In: New drugs in general practice: prescribing patterns and external influences, ed. FlorentinusSR. Utrecht: Utrecht University, 2006; 5364.
  • 12
    Layton D, Souverein PC, Heerdink ER, Shakir SAW, Egberts AGC. Prescriber adoption of newly approved selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf 2008; 17: 116874.
  • 13
    Williamson PM. The adoption of new drugs by doctors practising in group and solo practice. Soc Sci Med 1975; 9: 2336.
  • 14
    Steffensen FH, Sorenson HT, Oleson F. Diffusion of drugs in Danish general practice. Family Prac 1999; 16: 40713.
  • 15
    Dean T. Time for carrots and sticks on ADR reporting? Prescriber 2006; 17: 9.